Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness

Nov 10, 2017
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindness-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindness-0